MAP.AU Microba Life Sciences Ltd
- Market cap
- AUD 25.6M
- P/E
- -
- P/B
- 1.05x
- ROE
- -166.8%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is MAP.AU undervalued?
Graham numberThe Graham number of Microba Life Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Microba Life Sciences Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-166.8%), below 10%.
ROA 0/1
Return on assets (-102.1%) is below the industry median (-0.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-3.5%) is below the industry median (-1.5%).
Revenue Growth 2/2
Revenue grew 39.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (16.8%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.1x) is below the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Microba Life Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for path…
Full company profileMicroba Life Sciences Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Microba Life Sciences Ltd annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.83M | 2.91M | 3.73M | 4.69M | 5.42M | 12.1M | 15.7M | 14.8M | 29.8M |
| Gross Profit | -2.49M | -4.05M | -5.30M | 2.37M | -6.77M | 5.91M | 7.44M | -11.7M | -20.6M |
| Operating Income | -4.79M | -7.41M | -9.57M | -16.3M | -20.2M | -26.8M | -24.6M | -20.3M | -37.6M |
| EBITDA | -3.93M | -5.53M | -6.28M | -9.86M | -17.1M | -17.1M | -10.5M | -15.9M | -28.8M |
| Net Income | -4.73M | -6.65M | -7.52M | -11.5M | -12.7M | -19.9M | -14.9M | -20.7M | -40.7M |
| EPS | -0.02 | -0.02 | -0.03 | -0.04 | -0.04 | -0.05 | -0.03 | -0.03 | -0.07 |
| Balance Sheet | |||||||||
| Total Assets | 14.0M | 10.8M | 18.5M | 39.5M | 47.0M | 58.0M | 47.4M | 39.8M | 39.8M |
| Total Liabilities | 1.43M | 3.10M | 3.55M | 5.94M | 8.23M | 16.8M | 14.9M | 15.4M | 15.4M |
| Shareholders' Equity | 12.6M | 7.70M | 14.9M | 33.5M | 38.6M | 41.2M | 32.5M | 24.4M | 24.4M |
| Cash & Short-term Investments | 11.0M | 6.90M | 13.0M | 30.6M | 32.0M | 20.9M | 11.7M | 7.95M | 7.95M |
| Total Debt | 406K | 564K | 269K | 1.33M | 1.14M | 1.58M | 3.23M | 4.11M | 4.11M |
| Cash Flow | |||||||||
| Operating Cash Flow | -3.62M | -4.32M | -7.18M | -10.4M | -12.4M | -15.6M | -12.0M | -12.4M | -26.7M |
| Capital Expenditure | 836K | 856K | 672K | 1.87M | 3.04M | 4.38M | 2.90M | 240K | 203K |
| Free Cash Flow | -4.46M | -5.18M | -7.85M | -1.87M | -15.4M | -19.9M | -14.9M | -12.6M | -26.9M |
| Ratios | |||||||||
| ROE | -37.7% | -86.3% | -50.4% | -34.2% | -32.9% | -48.4% | -46.0% | -85.0% | -166.8% |
| ROA | -33.8% | -61.5% | -40.7% | -29.1% | -27.0% | -34.4% | -31.5% | -52.1% | -102.1% |
| Net Profit Margin | -258.9% | -228.6% | -201.6% | -244.6% | -233.9% | -164.9% | -95.3% | -140.4% | -136.7% |
| Debt to Equity | 0.03x | 0.07x | 0.02x | 0.04x | 0.03x | 0.04x | 0.10x | 0.17x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Microba Life Sciences Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 596K | 0.00 | - |
| 2021 | AUD 425K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Microba Life Sciences Ltd
- Insiders 41.97%
- Institutions 24.12%
- Public & others 33.92%
- Shares outstanding 743M
- Free float 291M
Microba Life Sciences Ltd company profile
- Company name
- Microba Life Sciences Ltd
- Ticker
- MAP.AU
- ISIN
- AU0000209868
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 324 Queen Street, Brisbane, QLD, Australia, 4000
- Phone
- 61 13 0097 4621
- Website
- microba.com
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Microba Life Sciences Ltd management
10- Mr. James HeathCFO & Company Secretary
- Dr. Luke ReidChief Executive Officer (Leave of Absence)
- Mr. Geoffrey C. CockerillInterim Chief Executive Officer
- Prof. Philip HugenholtzCo-Founder & Chair of Scientific Advisory Board
- Dr. David WoodChief Technology Officer
- Prof. Lutz KrauseChief Scientific Officer
- Dr. Nicola AngelHead of Laboratory Operations & Laboratory Director
- Mr. Keith ByrneHead of Test Operations
- Eric DaviesChief Revenue Officer
- Mr. Alaster Stockwell-JonesManaging Director of UK